Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) Shares Outstanding (Weighted Average) (2016 - 2025)

Bioadaptives' Shares Outstanding (Weighted Average) history spans 8 years, with the latest figure at $12.0 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 46.17% to $12.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.0 million, a 46.17% increase, with the full-year FY2025 number at $12.0 million, up 46.17% from a year prior.
  • Shares Outstanding (Weighted Average) hit $12.0 million in Q4 2025 for Bioadaptives, up from $10.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for BDPT hit a ceiling of $1.1 billion in Q3 2024 and a floor of $6.0 million in Q4 2023.
  • Historically, Shares Outstanding (Weighted Average) has averaged $235.2 million across 5 years, with a median of $43.7 million in 2021.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): surged 553.99% in 2023 and later tumbled 99.08% in 2025.
  • Tracing BDPT's Shares Outstanding (Weighted Average) over 5 years: stood at $33.7 million in 2021, then soared by 214.17% to $106.0 million in 2022, then crashed by 94.37% to $6.0 million in 2023, then soared by 37.57% to $8.2 million in 2024, then surged by 46.17% to $12.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for BDPT at $12.0 million in Q4 2025, $10.9 million in Q3 2025, and $9.9 million in Q2 2025.